Merus N.V. - Common Shares (NQ:MRUS)

What a $19 Million CyberArk Buy Signals for Long-Term Investors Amid a 43% Stock Surge ↗

December 23, 2025

The stock has already soared, the numbers keep accelerating, and one concentrated fund just made it a core holding anyway.

What a $22 Million Bet on STAAR Surgical Signals After Third-Quarter Earnings and a 15% Market Lag ↗

Performance

52-Week Range 7.4% below 52-week high

90.00

90.0052W Low 97.1452W High

Merus N.V. - Common Shares (MRUS) traded between $90.00 and $97.14 over the past 52 weeks and last traded at $90.00, 7.4% below its 52-week high.

Past 12 Months

N/A

-4.4%

YTD

1Y -$4.15

MRUS was -4.4% over the past year.

12 Months vs Market

MRUS

-4.4%

DIA

+9.9%

SPY

+15.0%

QQQ

+23.7%

IWM

+15.4%

Over the past 12 months MRUS returned -4.4% versus DIA (Dow) +9.9%, SPY (S&P 500) +15.0%, QQQ (Nasdaq 100) +23.7% and IWM (Russell 2000) +15.4%.

Volume & Liquidity

1.6M

More News

December 23, 2025

Merus Stock Soars To All-Time High As Genmab Announces $8B Takeover — Analysts Turn Cautious, Retail Crowd Cheers The Deal ↗

September 30, 2025

Via Stocktwits

Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period

December 12, 2025

From Genmab A/S

Via Business Wire

Halper Sadeh LLC Encourages CADE, THS, CMA, MRUS Shareholders to Contact the Firm to Discuss Their Rights

December 03, 2025

With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance? ↗

December 03, 2025

Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away ↗

December 03, 2025

Terns Stock Surges 300% in One Year — What a New $43 Million Position Signals for Investors ↗

December 03, 2025

Relay Therapeutics Stock Has Jumped 60% in a Year — And One Investor Just Bought Nearly 4 Million More Shares ↗

December 03, 2025

Halper Sadeh LLC Encourages EXAS, NVRI, MRUS Shareholders to Contact the Firm to Discuss Their Rights

November 22, 2025

Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety

October 24, 2025

From Merus N.V.

HALPER SADEH LLC ENCOURAGES MTSR, HOLX, MRUS SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

October 23, 2025

Merus Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS

October 23, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 14, 2025

From Merus N.V.

Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 13, 2025

From Merus N.V.

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates PINC, ODP, PRO, MRUS on Behalf of Shareholders

October 09, 2025

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates EA, MRUS, BRY, SMLR on Behalf of Shareholders

October 07, 2025

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Electronic Arts Inc. (Nasdaq - EA), Merus N.V. (Nasdaq – MRUS), Berry Corporation (Nasdaq - BRY), Semler Scientific, Inc. (Nasdaq – SMLR)

October 07, 2025

From Brodsky & Smith LLC

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PRO, EA, MRUS on Behalf of Shareholders

October 04, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EA and MRUS on Behalf of Shareholders

Unusual volume stocks are being observed in Thursday's session. ↗

October 02, 2025

Via Chartmill

October 01, 2025